Intercept Pharma (ICPT) Tops Q2 EPS by 88c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oil jumps to $105 a barrel after Middle East tanker attacks escalate
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
- S&P 500 ends down as oil tops $100 per barrel
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- White House copper tariff plan stalls amid affordability concerns, sources say
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Intercept Pharmaceuticals (ICPT) PT Lowered to $18 at H.C. Wainwright
August 2, 2021 6:34 AM EDTH.C. Wainwright analyst Ed Arce lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $18.00 (from $21.00) while maintaining a Neutral rating, citing an uncertain road ahead in NASH.
The analyst commented, " As previously expected, the current Ocaliva label issued by the FDA on May 26 establishes new contraindications for patients with: (1) decompensated cirrhosis; (2) a prior decompensation event; or even (3) compensated cirrhosis who have or develop evidence of portal... More
Intercept Pharmaceuticals (ICPT) PT Lowered to $28 at Cowen
July 30, 2021 7:11 AM EDTCowen analyst Ritu Baral lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $28.00 (from $47.00) while maintaining a Market Perform rating.
The analyst commented, "ICPT reported 2Q21 Ocaliva PBC sales of $96.6MM beating consensus ($82.4M). FY21 revenue guidance of $325-$340MM was... More
Intercept Pharmaceuticals (ICPT) PT Lowered to $30 at Needham & Company
July 29, 2021 1:24 PM EDTNeedham & Company analyst Joseph Stringer lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $30.00 (from $34.00) while maintaining a Buy rating.
The analyst commented, "ICPT reported 2Q21 financial results today, and we spoke w/ mgmt following the call. Ocaliva (OCA) WW sales of... More
